EWTX Trading Analysis - 10/28/2026 11:04 AM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for EWTX (Edgewise Therapeutics, a clinical-stage biopharma focused on neuromuscular disease):

• Pipeline updates from ongoing trials inDuchenne muscular dystrophy (EDG-5506) have been a recurring catalyst, with topline data readouts historically driving sharp moves.
• Biotech sector sentiment has been sensitive to FDA guidance and financing activity; no confirmed earnings date in provided data, but fiscal year end was 2025-12-01 per fundamentals.
• Low beta (0.49) suggests EWTX moves less with broad market than typical small-cap biotech.
• Headlines context: Any trial milestone or partnership news could shift the balanced options sentiment; current embedded data shows no directional options conviction.

This news context is separated from the strict data analysis below, which uses only embedded figures.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS (source: FinWin fundamentals local):

• Trailing P/E: 3.70; Trailing EPS: -1.85 (negative earnings, typical for pre-revenue biotech).
• Market Cap: 4346875100.00; Shares Outstanding: 108604000.00.
• Dividend Yield: 0.00; No dividend rate or ex-date.
• Beta: 0.49 (low systematic risk vs market).
• 52-Week High: 48.51; 52-Week Low: 15.66 (current ~39.58 sits mid-range).
• Institutional Percent: 40.61%.
• Average Volume: 1406000.00; Historical Volatility: 46.02%.
• PEG Ratio: null; Forward P/E: null; Profit Margins: null; ROE: null; Debt/Equity: null; Free Cash Flow: null; Revenue: null; Revenue Growth: null.
• Analyst consensus and target price: null (no recommendation key or mean target).

Fundamentals show a loss-making biotech with low beta and mid-cap scale. Negative EPS and missing margin/data diverge from neutral technical posture; valuation via trailing P/E is not meaningful due to negative earnings. No fundamental strength in profitability, but low beta is a relative stability point.

Current Market Position

From DAILY and MINUTE data: Current price (2026-10-27 close) 39.58. Minute bars show 2026-10-28 10:35 close 40.08, intraday high 40.09, low 39.78, with volume building to 106961 at last bar (momentum up late session).

Recent daily action: 2026-09-16 close 45.44 → 2026-10-27 close 39.58 (downtrend from Sept high). 30-day range high 48.51, low 35.63.

Technical Analysis

SMA alignment: SMA 5 (39.49) > SMA 20 (39.18) but both below SMA 50 (41.66) — bearish longer-term bias, short-term neutral-to-positive crossover. RSI 48.97 = neutral momentum. MACD negative with histogram -0.13 = mild bearish pressure. Price inside Bollinger (middle 39.18, upper 41.66, lower 36.70) = no squeeze/expansion signal. 30-day high 48.51, low 35.63; current 39.58 is ~33% up from low, ~19% below high.

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS: Call dollar vol 0.00, Put dollar vol 0.00, total 0.00, sentiment "Balanced", 348 total options analyzed, 0 true sentiment (filter 0%). No directional conviction.

Call vs Put: 0% / 0% — neutral. Options flow suggests near-term expectations are non-directional. Divergence: minute bars show late-session upward momentum, but options show no conviction — sentiment not confirming price drift.

Key Price Levels (Observational Only)